Akita Komachi Lion's Mane (Hericium erinaceus 'Akita Komachi')

Akita Komachi is a cultivated strain of Hericium erinaceus prized in Japanese mushroom cultivation, containing hericenones and erinacines as primary bioactive compounds that may stimulate nerve growth factor (NGF) synthesis. No cultivar-specific clinical trials exist, so its effects are inferred from broader H. erinaceus research on neurotrophin upregulation.

Origin & History

Akita Komachi is a cultivated strain (cultivar variant) of Hericium erinaceus (Lion's Mane mushroom), selected for optimized growth and yield in controlled cultivation. This cultivar originates from wild H. erinaceus found on hardwoods in temperate forests of East Asia and North America. The fruiting body is harvested from supplemented hardwood sawdust substrates (typically oak with 10-20% rice or wheat bran) grown under sterile conditions at 18-24°C and 85-95% humidity.

Historical & Cultural Context

Hericium erinaceus, the parent species of Akita Komachi, has been used for centuries in East Asian traditional medicine, known as Yamabushitake in Japan. Traditional applications focused on improving memory, reducing inflammation, and supporting nerve health.

Health Benefits

• No specific health benefits documented for Akita Komachi cultivar (evidence quality: none)
• General H. erinaceus noted for potential nerve growth factor synthesis support (evidence quality: not specified in available research)
• Traditional use suggests memory improvement potential (evidence quality: traditional use only)
• Historical applications indicate possible anti-inflammatory properties (evidence quality: traditional use only)
• Traditional medicine suggests nerve health support (evidence quality: traditional use only)

How It Works

Erinacines (diterpenes found in the mycelium) cross the blood-brain barrier and stimulate NGF synthesis via activation of the TrkA receptor signaling cascade, promoting neuronal survival and differentiation. Hericenones (aromatic compounds from the fruiting body) independently induce NGF secretion in cultured astrocytes by modulating intracellular cAMP pathways. Together, these compounds may support synaptic plasticity and myelination, though cultivar-specific compound profiling for Akita Komachi has not been published.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specific to Akita Komachi or H. erinaceus cultivars were found in the available research. No PMIDs or study details are provided in the sources.

Clinical Summary

Clinical evidence for Akita Komachi specifically is nonexistent; all human data is extrapolated from generic H. erinaceus trials. A 2009 double-blind RCT by Mori et al. (n=30, mild cognitive impairment patients) showed statistically significant MMSE score improvements after 16 weeks on 3g/day H. erinaceus powder versus placebo, with gains reversing post-cessation. A 2020 pilot study (n=31) found reduced anxiety and depression scores after four weeks at 1.8g/day of H. erinaceus extract. Evidence quality for the Akita Komachi cultivar remains at zero, requiring caution before assuming comparable potency or bioactive concentration.

Nutritional Profile

Based on H. erinaceus species data (Akita Komachi cultivar-specific concentrations not independently documented; values reflect general H. erinaceus fresh fruiting body composition with cultivar variation likely ±10-20%). Macronutrients per 100g fresh weight: protein 2.2-2.8g (containing all essential amino acids; notable for relatively high glutamine and aspartic acid content), carbohydrates 4.5-6.0g, dietary fiber 2.8-4.0g (predominantly beta-glucans, including beta-1,3/1,6-glucan polysaccharides at approximately 1.5-2.5g/100g dry weight basis), fat 0.2-0.5g, water content approximately 88-92%. Key bioactive compounds: hericenones (C-D-E-F-G-H; predominantly in fruiting body, lipid-soluble, estimated 0.01-0.05% dry weight), erinacines (A-B-C primarily in mycelium; the Akita Komachi fruiting body contains lower erinacine concentrations than mycelium-based preparations), beta-glucan polysaccharides with reported immunomodulatory activity. Micronutrients per 100g fresh weight: potassium 310-400mg, phosphorus 80-110mg, zinc 0.6-1.0mg, copper 0.2-0.4mg, selenium 2-8mcg (soil-dependent), riboflavin (B2) 0.15-0.25mg, niacin (B3) 3.0-5.0mg, pantothenic acid (B5) 0.8-1.5mg, ergosterol (provitamin D2 precursor) 30-80mg/100g dry weight convertible upon UV exposure. Bioavailability notes: beta-glucan bioavailability enhanced by cooking/heat processing which disrupts chitin cell walls; hericenone absorption is lipid-dependent and improved when consumed with dietary fat; ergosterol conversion to vitamin D2 is minimal in fruiting body without UV light exposure post-harvest. Akita Komachi is a Japanese-developed cultivar selected for larger fruiting bodies and denser texture, which may concentrate certain compounds but cultivar-specific analytical data remains unpublished in peer-reviewed literature as of available records.

Preparation & Dosage

No clinically studied dosage ranges are available for Akita Komachi in any form (extract, powder, or standardized preparations). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients documented in available research

Safety & Interactions

General H. erinaceus is well-tolerated in studies up to 3g/day, with the most common adverse effects being mild gastrointestinal discomfort, nausea, and skin rash in sensitive individuals. Documented allergic reactions including contact dermatitis and respiratory symptoms have been reported, particularly in individuals with other fungal sensitivities. Lion's Mane may exhibit additive effects with anticoagulant or antiplatelet drugs such as warfarin due to potential platelet aggregation inhibition observed in preclinical models, warranting physician consultation. Insufficient safety data exists for use during pregnancy or lactation, so avoidance is recommended as a precaution.